EX-99.1 2 d19327dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Interim Consolidated Financial Statements

(In thousands of United States dollars)

 

THERATECHNOLOGIES INC.

 

Three and six-month periods ended May 31, 2020 and 2019

(Unaudited)


THERATECHNOLOGIES INC.

Table of Contents

(In thousands of United States dollars)

(Unaudited)

 

 

 

     Page  

Interim Consolidated Statements of Financial Position

     1  

Interim Consolidated Statements of Comprehensive Loss

     2  

Interim Consolidated Statements of Changes in Equity

     3  

Interim Consolidated Statements of Cash Flows

     4  

Notes to Interim Consolidated Financial Statements

     5 - 18  

 


THERATECHNOLOGIES INC.

Interim Consolidated Statements of Financial Position

(In thousands of United States dollars)

As at May 31, 2020 and November 30, 2019

(Unaudited)

 

 

 

                    May 31,             November 30,  
      Note      2020     2019  

Assets

       

Current assets

       

Cash

      $ 21,440     $ 28,661  

Bonds and money market funds

        10,203       11,964  

Trade and other receivables

        12,191       10,116  

Inventories

     5        24,735       20,929  

Prepaid expenses and deposits

        3,207       3,874  

Derivative financial assets

              387       637  

Total current assets

              72,163       76,181  

Non-current assets

       

Bonds and money market funds

        -       619  

Right-of-use assets

        2,745       -  

Property and equipment

        962       1,071  

Intangible assets

        26,121       27,480  

Other asset

              9,763       12,204  

Total non-current assets

              39,591       41,374  

Total assets

            $ 111,754     $ 117,555  

Liabilities

       

Current liabilities

       

Accounts payable and accrued liabilities

      $ 30,606     $ 31,173  

Provisions

     6        3,054       2,484  

Current portion of long-term obligations

     7        3,487       3,417  

Current portion of lease liabilities

     9        373       -  

Deferred revenue

              28       70  

Total current liabilities

              37,548       37,144  

Non-current liabilities

       

Long-term obligations

     7        4,602       4,570  

Convertible unsecured senior notes

     8        51,553       50,741  

Lease liabilities

     9        2,600       -  

Other liabilities

              29       266  

Total non-current liabilities

              58,784       55,577  

Total liabilities

              96,332       92,721  

Equity

       

Share capital

        287,312       287,035  

Equity component of convertible unsecured senior notes

        4,457       4,457  

Contributed surplus

        11,469       10,783  

Deficit

        (287,812     (277,462

Accumulated other comprehensive (loss) income

              (4     21  

Total equity

              15,422       24,834  

Total liabilities and equity

            $ 111,754     $ 117,555  

The accompanying notes are an integral part of these interim consolidated financial statements.

 

1


THERATECHNOLOGIES INC.

Interim Consolidated Statements of Comprehensive Loss

(In thousands of United States dollars, except per share amounts)

Three-month periods and six-month periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

             For the three-month
    periods ended May 31,
     For the six-month
    periods ended May 31,
 
      Note     2020      2019      2020      2019  

Revenue

     3     $ 17,162      $ 15,609      $ 32,881      $ 30,705  

Operating expenses

             

Cost of sales

             

Cost of goods sold

       5,769        5,346        11,169        10,156  

Other production-related costs

       391        18        531        52  

Amortization of other asset

       1,220        1,221        2,441        2,442  

Research and development expenses

       3,622        2,285        7,041        4,812  

Selling expenses

       6,941        6,972        13,302        12,420  

General and administrative expenses

       3,706        1,784        6,276        3,300  
           

Total operating expenses

             21,649        17,626        40,760        33,182  

Loss from operating activities

       (4,487      (2,017      (7,876      (2,477

Finance income

     4       80        292        246        627  

Finance costs

     4       (1,399      (1,449      (2,717      (2,552
           
               (1,319      (1,157      (2,471      (1,925

Net loss for the period

           $ (5,806    $ (3,174    $ (10,350    $ (4,402

Other comprehensive income (loss), net of tax

             

Items that may be reclassified to net profit (loss) in the future:

             

Net change in fair value of FVOCI financial assets,
net of tax

       9        30        19        62  

Exchange differences on translation

       (42      5        (44      5  
           
               (33      35        (25      67  

Total comprehensive loss for the period

           $ (5,839    $ (3,139    $ (10,375    $ (4,335

Basic and diluted loss per share

     10 (c)      (0.08      (0.04      (0.13      (0.06

The accompanying notes are an integral part of these interim consolidated financial statements.

 

2


THERATECHNOLOGIES INC.

Interim Consolidated Statements of Changes in Equity

(In thousands of United States dollars, except per share amounts)

Six-month periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

      For the six-month period ended May 31, 2020  
     Share capital      Equity                  Accumulated        
                   component
                 other
       
     Number
                    of convertible
             Contributed
                  comprehensive
       
      of shares      Amount      notes      surplus     Deficit     income (loss)                 Total  

Balance as at November 30, 2019

     76,953,411      $ 287,035      $ 4,457      $ 10,783     $ (277,462   $ 21     $ 24,834  

Total comprehensive loss for the period

                 

Net loss for the period

     -        -        -        -       (10,350     -       (10,350

Other comprehensive income:

                 

Net change in fair value of financial assets at fair value through other comprehensive income, net of tax

     -        -        -        -       -       19       19  

Exchange differences on translation

     -        -        -        -       -       (44     (44
               

Total comprehensive loss for the period

     -        -        -        -       (10,350     (25     (10,375

Transactions with owners,
recorded directly in equity

                 

Share-based compensation plan:

                 

Share-based compensation for stock option plan

     -        -        -        818       -       -       818  

Exercise of stock options:

                 

Monetary consideration

     60,000        145        -        -       -       -       145  

Attributed value

     -        132        -        (132     -       -       -  
               

Total contributions by owners

     60,000        277        -        686       -       -       963  

Balance as at May 31, 2020

     77,013,411      $ 287,312      $ 4,457      $ 11,469     $ (287,812   $ (4   $ 15,422  
                                                             
      For the six-month period ended May 31, 2019  
     Share capital      Equity                  Accumulated        
                   component
                 other
       
     Number
            of convertible
     Contributed
          comprehensive
       
      of shares      Amount      notes      surplus     Deficit     income (loss)     Total  

Balance as at November 30, 2018

     76,877,679      $ 286,828      $ 4,457      $ 8,788     $ (264,966   $ (95   $ 35,012  

Total comprehensive (loss) income for the period

                 

Net loss for the period

     -        -        -        -       (4,402     -       (4,402

Other comprehensive income:

                 

Net change in fair value of financial assets at fair value through other comprehensive income, net of tax

     -        -        -        -       -       62       62  

Exchange differences on translation

     -        -        -        -       -       5       5  
               

Total comprehensive (loss) income for the period

     -        -        -        -       (4,402     67       (4,335

Transactions with owners,
recorded directly in equity

                 

Issuance of common shares – Katana

     900        5        -        -       -       -       5  

Share-based compensation plan:

                 

Share-based compensation for stock option plan

     -        -        -        566       -       -       566  

Exercise of stock options:

                 

Monetary consideration

     74,832        110        -        -       -       -       110  

Attributed value

     -        92        -        (92     -       -       -  
               

Total contributions by owners

     75,732        207        -        474       -       -       681  

Balance as at May 31, 2019

     76,953,411      $ 287,035      $ 4,457      $ 9,262     $ (269,368   $ (28   $ 31,358  

The accompanying notes are an integral part of these interim consolidated financial statements.

 

3


THERATECHNOLOGIES INC.

Interim Consolidated Statements of Cash Flows

(In thousands of United States dollars)

Three-month periods and six-month periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

                  For the three-month
periods ended May 31,
       For the six-month
periods ended May 31,
 
        Note        2020        2019        2020        2019  

Cash provided from (used in)

          $          $          $          $    

Operating

                        

Net loss

            (5,806        (3,174        (10,350        (4,402

Adjustments for

                        

Depreciation of property and equipment

            61          60          121          65  

Amortization of intangible assets and other assets

            1,939          1,862          3,800          3,571  

Amortization of right-of-use asset

            109          -          218          -  

Share-based compensation for stock option plan and stock appreciation rights

            454          320          819          584  

Write-down of inventories

       5          391          -          394          3  

Change in fair value of derivative financial assets

            102          439          249          260  

Change in fair value of liability related to deferred stock unit plan

            (95        (433        (240        (256

Interest on convertible unsecured senior notes

            842          834          1,644          1,646  

Interest income

            (80        (292        (246        (627

Foreign exchange

            23          203          36          124  

Accretion expense

            521          448          1,023          805  

Lease inducements and amortization

                  -          228          -          228  
            (1,539        495          (2,532        2,001  

Change in operating assets and liabilities

                        

Trade and other receivables

            (2,301        (5,435        (2,071        (2,469

Inventories

            (4,424        (1,359        (4,168        (1,780

Prepaid expenses and deposits

            (31        (159        669          (61

Accounts payable and accrued liabilities

            5,040          (3,748        (351        (4,821

Provisions

            164          (130        570          511  

Deferred revenue

            (9        27          (42        43  
           
                    (1,561        (10,804        (5,393        (8,577

Cash flows used in operating activities

            (3,100        (10,309        (7,925        (6,576

Financing

                        

Proceeds from exercise of stock options

            145          70          145          110  

Payments of lease liabilities

            (135        -          (276        -  

Interest paid on convertible unsecured senior notes

                  -          -          (1,653        (1,764

Cash flows from (used in) financing activities

            10          70          (1,784        (1,654

Investing

                        

Acquisition of bonds and money market funds

            (21        (44        (51        (117

Proceeds from sale of bonds and money market funds

            859          575          2,258          1,932  

Interest received

            107          329          298          688  

Acquisition of intangible assets

            -          (45        -          (2,024

Acquisition of derivative financial assets

            (17        -          (17        -  

Acquisition of property and equipment

                  (10        (681        (13        (1,157

Cash flows from (used in) investing activities

                  918          134          2,475          (678

Net change in cash

            (2,172        (10,105        (7,234        (8,908

Cash, beginning of period

            23,600          40,194          28,661          38,997  

Effect of foreign exchange on cash

                  12          -          13          -  
           

Cash, end of period

                $ 21,440        $ 30,089        $ 21,440        $ 30,089  

See Note 11 for supplemental cash flow disclosures.

The accompanying notes are an integral part of these interim consolidated financial statements.

 

4


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

Theratechnologies Inc. is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV.

The interim consolidated financial statements include the accounts of Theratechnologies Inc. and its wholly-owned subsidiaries (together referred to as the “Company” and individually as the “subsidiaries of the Company”).

Theratechnologies Inc. is governed by the Business Corporations Act (Québec) and is domiciled in Québec, Canada. The Company is located at 2015 Peel Street, Montréal, Québec, H3A 1T8.

 

 

1.

Basis of preparation

 

  (a)

Accounting framework

These unaudited interim consolidated financial statements (“interim financial statements”), including comparative information, have been prepared using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and in accordance with International Accounting Standard (“IAS”) 34, Interim Financial Reporting.

Certain information, in particular the accompanying notes normally included in the annual consolidated financial statements prepared in accordance with IFRS, has been omitted or condensed. These interim financial statements do not include all disclosures required under IFRS and, accordingly, should be read in conjunction with the annual consolidated financial statements for the year ended November 30, 2019 and the notes thereto.

These interim financial statements have been authorized for issue by the Company’s Audit Committee on July 14, 2020.

 

 

  (b)

Basis of measurement

The Company’s interim financial statements have been prepared on a going concern and historical cost bases, except for bonds and money market funds, derivative financial assets, liabilities related to cash-settled share-based arrangements and derivative financial liabilities, which are measured at fair value. Effective December 1, 2019, lease liabilities are measured at the present value of lease payments not paid at commencement date. See note 2(a) below. Equity-classified share-based payment arrangements are measured at fair value at grant date pursuant to IFRS 2, Share-based Payment.

The methods used to measure fair value are discussed further in Note 13.

 

 

5


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

1.

Basis of preparation (continued)

 

 

  (c)

Use of estimates and judgments

The preparation of the Company’s interim financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim financial statements, and the reported amounts of revenues and expenses during the reporting periods.

Information about critical judgments in applying accounting policies and assumptions and estimation uncertainties that have the most significant effect on the amounts recognized in the interim financial statements are disclosed in Note 1 of the annual consolidated financial statements as at November 30, 2019.

 

  (d)

Functional and presentation currency

The Company’s functional currency is the United States dollar (“USD”).

All financial information presented in USD has been rounded to the nearest thousand.

 

 

2.

Significant accounting policies

The significant accounting policies as disclosed in the Company’s annual consolidated financial statements for the year ended November 30, 2019 have been applied consistently in the preparation of these interim financial statements, except for the adoption of IFRS 16, Leases, as described in the Company’s first quarter financial statements of 2020.

 

 

6


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

3.

Revenue

Net sales by product were as follows:

 

   
     For the three-month periods ended May 31,    
      2020      2019    

  EGRIFTA® and EGRIFTA SVTM net sales

   $ 9,269      $ 8,639    

  Trogarzo® net sales

     7,893        6,970    
     $ 17,162      $ 15,609    
                   
     For the six-month periods ended May 31,    
      2020      2019    

  EGRIFTA® and EGRIFTA SVTM net sales

   $ 17,784      $ 17,601    

  Trogarzo® net sales

     15,097        13,104    
     $ 32,881      $ 30,705    

Net sales by geography were as follows:

 

 

     For the three-month periods ended May 31,    
      2020      2019    

  Canada

   $ 122      $ 86    

  United States

     17,040        15,523    
     $ 17,162      $ 15,609    
                   
     For the six-month periods ended May 31,    
      2020      2019    

  Canada

   $ 231      $ 86    

  United States

     32,650        30,619    
     $ 32,881      $ 30,705    

 

7


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

4.

Finance income and finance costs

 

   
     For the three-month periods ended May 31,  
     2020     2019  
     

Interest income

   $ 80     $ 292  

Finance income

     80       292  

Accretion expense

     (521     (448

Interest on convertible unsecured senior notes

     (842     (834

Bank charges

     (16     (14

Net foreign currency loss

     (13     (147

Loss on financial instruments carried at fair value

     (7     (6
     

Finance costs

     (1,399     (1,449
     

Net finance cost recognized in net profit or loss

   $ (1,319   $ (1,157
                  
     For the six-month periods ended May 31,  
     2020     2019  
     

Interest income

   $ 246     $ 627  

Finance income

     246       627  

Accretion expense

     (1,023     (805

Interest on convertible unsecured senior notes

     (1,644     (1,646

Bank charges

     (16     (14

Net foreign currency loss

     (25     (83

Loss on financial instruments carried at fair value

     (9     (4
     

Finance costs

     (2,717     (2,552

Net finance cost recognized in net profit or loss

   $ (2,471   $ (1,925

 

8


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

5.

Inventories

Inventories were written down in 2020 to net realizable value by an amount of $394 (2019 - $3), which is recorded in cost of sales.

A provision of $391 on excess stock of EGRIFTA® was recorded as a result of the Company’s decision to switch patients to and only actively commercialize the new EGRIFTA SVTM formulation in the United States.

 

6.

Provisions

 

      Chargebacks
and rebates
    Returns     Other     Total  

Balance as at November 30, 2018

   $ 895     $         119     $             -     $         1,014  

Provisions made

     10,818       174       55       11,047  

Provisions used

     (9,531     (46     -       (9,577

Balance as at November 30, 2019

     2,182       247       55       2,484  

Provisions made

     5,424       65       1,413       6,902  

Provisions used

     (5,592     (2     (738     (6,332
         

Balance as at May 31, 2020

     2,014       310       730       3,054  

 

9


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

7.

Long-term obligations

The movement in the long-term obligations is as follows.

 

      Commercialization
rights – Trogarzo®
North American
Territory
    
Commercialization
rights –  Trogarzo®
European Territory
     Total  

  Balance as at November 30, 2018

   $ -      $ -      $ -  

  Additions

     6,765                    4,557                11,322  

  Accretion expense

     152        13        165  

  Payment

     (3,500      -        (3,500

  Balance as at November 30, 2019

     3,417        4,570        7,987  

  Accretion expense

     70        32        102  

  Balance as at May 31, 2020

     3,487        4,602        8,089  

  Current portion

     (3,487      -        (3,487
       

  Non-current portion

   $ -      $ 4,602      $ 4,602  

 

8.

Convertible unsecured senior notes

The movement in the carrying value of the convertible unsecured senior notes is as follows:

 

Convertible unsecured senior notes as at November 30, 2018

   $                   49,233  

Accretion expense

     1,508  

Convertible unsecured senior notes as at November 30, 2019

   $ 50,741  

Accretion expense

     812  
   

Convertible unsecured senior notes as at May 31, 2020

   $ 51,553  

 

10


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

9.

Lease liabilities

 

     

Carrying

value

 

Balance as at December 1, 2019

   $       3,192  

Accretion expense

     109  

Lease payments

     (276

Effect of change in exchange rates

     (52

Balance as at May 31, 2020

     2,973  

Current portion

     (373
   

Non-current portion

   $ 2,600  

 

11


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

10.

 Share capital

 

  (a)

Stock options

The Company has established a stock option plan (the “Plan”) under which it can grant its directors, officers, employees, researchers and consultants non-transferable options for the purchase of common shares. The exercise date of an option may not be later than 10 years after the grant date. A maximum number of 6,580,000 options can be granted under the Plan. Generally, the options vest at the grant date or over a period of up to three years. As at May 31, 2020, 1,172,697 options could still be granted by the Company (May 31, 2019 – 1,630,017) under the Plan.

The Company issued 487,421 options to Paul Lévesque, the President and Chief Executive Officer of the Company, on April 15, 2020 as inducement to enter into his employment agreement with the Company. These 487,421 options vest equally over a three-year period beginning on April 15, 2021, have an exercise price of $2.87 and have a ten-year term.

The Company also issued an additional 590,300 options to its Senior management, employees and Board of Directors since the beginning of its fiscal year.

All options are to be settled by the physical delivery of the common shares.

Changes in the number of options outstanding during the past two years were as follows:

 

             Weighted average
exercise price
per option
 
      Number of options     CAD      USD  

Options as at November 30, 2018

     2,172,705     $         3.15      $                 2.37  

Granted

     406,400       8.19        6.20  

Forfeited

     (85,655     6.97        4.49  

Exercised (share price: CAD7.78 (USD5.82))

     (74,832     1.96        1.46  
       

Options outstanding as at May 31, 2019

     2,418,618       3.94        2.92  

Options as at November 30, 2019

     2,415,784       3.93        2.96  

Granted

     1,077,721       3.06        2.25  

Forfeited

     (130,146     5.08        3.63  

Exercised (share price: CAD3.77 (USD2.68))

     (60,000     3.38        2.40  

Options outstanding as at May 31, 2020

     3,303,359     $ 3.61      $ 2.62  

Options exercisable as at May 31, 2020

     2,097,584     $ 3.47      $ 2.52  

 

12


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

10.

Share capital (continued)

 

  (a)

Stock option plan (continued)

 

During the six-month period ended May 31, 2020, $818 (2019 - $566) were recorded as share-based compensation expense under the Plan. The fair value of options granted during the period was estimated at the grant date using the Black-Scholes model and the following weighted average assumptions:

 

      For the six-month periods ended May 31,  
      2020      2019  

Risk-free interest rate

     0.95%        2.15%  

Expected volatility

     70%        57%  

Average option life

     8.5 years        8 years  

Expected dividends

     -        -  

Grant-date share price

   $ 2.22 (CAD3.06)      $ 6.15 (CAD8.19)  

Option exercise price

   $ 2.22 (CAD3.06)      $ 6.15 (CAD8.19)  

The risk-free interest rate is based on the implied yield on a Canadian government zero-coupon issue, with a remaining term equal to the expected term of the option. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of the options is estimated taking into consideration the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation since it is the present policy of the Company to retain all earnings to finance operations and future growth.

 

13


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

10.

Share capital (continued)

 

  (a)

Stock option plan (continued)

 

The following table summarizes the measurement date weighted average fair value of stock options granted during the period ended:

 

For the six-month periods ended May 31,  
                     2020                                        2019  
     Number of
options
           

Weighted

average

grant date

fair value

           

Number of

options

           

Weighted

average

grant date

fair value

 

Options granted

     1,077,721      $          1.51 (CAD2.08)                 406,400      $          3.69 (CAD 4.92)  

The Black-Scholes model used by the Company to calculate option values was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which significantly differs from the Company’s stock option awards. This model also requires four highly subjective assumptions, including future stock price volatility and average option life, which greatly affect the calculated values.

 

  (b)

Stock appreciation rights (“SARs”)

On October 4, 2018, the Company’s Board of Directors approved a SARs plan for its consultants that entitles the grantee to receive a cash payment based on the increase in the stock price of the Company’s common shares from the grant date to the settlement date. The exercise date of an SAR may not be later than 10 years after the grant date. Generally, the SARs vest over a period up to three years.

During the six-month period ended May 31, 2020, $1 (2019 – $18) was recorded as share-based compensation expense for the SARs plan. Since these awards will be cash-settled, the fair value of SARs granted in 2019 (2020 – nil) is estimated at each reporting period using the Black-Scholes model and the following weighted average assumptions:

 

      Measurement date
as at
May 31, 2020
 

Risk-free interest rate

     0.53%  

Expected volatility

     66%  

Average option life in years

     6.75 years  

Period-end share price

     $1.79 (CAD2.47)  

SAR exercise price

     $5.85 (CAD8.05)  

 

14


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

10.

Share capital (continued)

 

  (b)

Stock appreciation rights (“SARs”) (continued)

 

The risk-free interest rate is based on the implied yield on a Canadian government zero-coupon issue, with a remaining term equal to the expected term of the SAR. The volatility is based on weighted average historical volatility adjusted for changes expected due to publicly available information. The life of the SARs is estimated taking into consideration the vesting period at the grant date, the life of the SARs and the average length of time similar grants have remained outstanding in the past. The dividend yield was excluded from the calculation since it is the present policy of the Company to retain all earnings to finance operations and future growth.

 

  (c)

Loss per share

For the three and six-month periods ended May 31, 2020, the weighted average number of common shares outstanding was calculated as follows:

 

      For the three-month periods ended May 31,  
      2020      2019  

Issued common shares as at March 1

     76,953,411        76,901,911  

Effect of share options exercised

     32,366        25,109  
     

Weighted average number of common shares

     76,985,777        76,927,020  
                   
     For the six-month periods ended May 31,  
      2020      2019  

Issued common shares as at December 1

     76,953,411        76,877,679  

Effect of share options exercised

     16,448        24,871  

Effect of issue of common shares - oncology platform

     -        475  
     

Weighted average number of common shares

     76,969,859        76,903,025  

For the three and six-month periods ended May 31, 2020, 3,303,359 (2019 - 2,458,618) share options, and 3,872,053 common shares potentially issuable from the conversion of the $57,500 aggregate principal amount of notes, that may potentially dilute earnings per share in the future were excluded from the weighted average number of diluted common shares calculation as their effect would have been anti-dilutive.

 

15


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

11.

Supplemental cash flow disclosures

The Company entered into the following transactions which had no impact on its cash flows:

 

     

            May 31,

2020

    

            May 31,

2019

 

Additions to property and equipment included in accounts payable and accrued liabilities

   $ 2      $ 36  

Additions to intangible assets included in accounts payable and accrued liabilities

     -        16  

Additions to intangible assets included in long-term obligations

     -        6,765  

Issuance of shares in connection with acquisition of intangible assets

     -        5  

Initial recognition of right-of-use assets and lease liability

     3,192        -  

Reclassification of other liabilities to right-of-use assets

     238        -  

 

12.

Financial instruments

The nature and extent of the Company’s exposure to risks arising from financial instruments are consistent with the disclosure in the annual consolidated financial statements as at November 30, 2019.

 

16


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

13.

Determination of fair values

Certain of the Company’s accounting policies and disclosures require the determination of fair value, for both financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability.

Financial assets and financial liabilities measured at fair value

In establishing fair value, the Company uses a fair value hierarchy based on levels as defined below:

 

  Level 1:

Defined as observable inputs such as quoted prices in active markets.

 

  Level 2:

Defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.

 

  Level 3:

Defined as inputs that are based on little or no observable market data, therefore requiring entities to develop their own assumptions.

Other financial assets and financial liabilities

The Company has determined that the carrying values of its short-term financial assets and financial liabilities, including cash, trade and other receivables and accounts payable and accrued liabilities, approximate their fair value because of the relatively short period to maturity of the instruments.

Bonds and money market funds and derivative financial assets and liabilities are stated at fair value, determined by inputs that are primarily based on broker quotes at the reporting date (Level 2).

The fair value of the convertible unsecured notes, including the equity portion, as at May 31, 2020 was approximately $43,700 (Level 1) based on market quotes.

Share-based payment transactions

The fair value of the employee stock options and SARs are measured based on the Black-Scholes valuation model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historical volatility adjusted for changes expected due to publicly available information), weighted average expected life of the instruments (based on historical experience and general option holder behaviour), expected dividends, and the risk-free interest rate (based on government bonds). Service and non-market performance conditions attached to the transactions, if any, are not taken into account in determining fair value.

 

17


THERATECHNOLOGIES INC.

Notes to Interim Consolidated Financial Statements (continued)

(In thousands of United States dollars except for share and per share amounts)

Periods ended May 31, 2020 and 2019

(Unaudited)

 

 

 

14.

Commitments

On February 4, 2020, the Company entered into an amended and restated licence agreement with the Massachusetts General Hospital (“MGH”) in order to benefit from its assistance and knowledge for the development of tesamorelin for the potential treatment of Non-Alcoholic Steatohepatitis (“NASH”) in the HIV population. Under the terms of the amended agreement, the MGH, through Dr. Steven Grinspoon, will provide services related to the study design, selection of optimal patient population, dosing, study duration and other safety matters and participate, if need be, in regulatory meetings with the FDA or the EMA. In consideration, we agreed to make certain milestone payments to the MGH related to the development of tesamorelin and a low single-digit royalty payment on all sales of EGRIFTA® and EGRIFTA SVTM above a certain threshold amount. The payment of the royalty will begin upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of Non-Alcoholic Fatty Liver Disease or NASH in the HIV population.

 

15.

Operating segments

The Company has a single operating segment. Almost all of the Company’s revenues are generated from one customer, RxCrossroads, which is domiciled in the United States.

 

       
                 2020      2019    
  RxCrossroads    $ 31,826      $         29,970    
    Others      1,055        735    
         $         32,881      $ 30,705    

All of the Company’s non-current assets are located in Canada as is the Company’s head office.

 

18